Interaction of prostanoid EP3 and TP receptors in guinea-pig isolated aorta: Contractile self-synergism of 11-deoxy-16,16-dimethyl PGE 2

British Journal of Pharmacology

Volumn 162, Issue 2, 2011, Pages 521-531

  Jones, Rl ^a   Woodward, Df ^b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b ALLERGAN INC   (United States)

Author keywords

AH 6809; BMS 180291; cloprostenol; contractile self synergism; I BOP; isolated smooth muscle preparation; latanoprost; prostanoid receptors; TP receptor antagonist

Indexed keywords

11 DEOXY 16,16 DIMETHYL PROSTAGLANDIN E2; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 8 CHLORODIBENZ[B,F][1,4]OXAZEPINE 10(11H) CARBOXYLIC ACID,2 [3[2 (FURANYLMETHYL)THIO]1 OXOPROPYL]HYDRAZINE; CLOPROSTENOL; HISTAMINE; IFETROBAN; LATANOPROST; PHENYLEPHRINE; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E2; PROSTANOID RECEPTOR; PROTEIN INHIBITOR; SC 51322; SULPROSTONE; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG POTENTIATION; GUINEA PIG; HEART MUSCLE CONTRACTILITY; IONIC STRENGTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

EID: 78650404870     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01039.x     Document Type: Article

References (53)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Ariens EJ, van Rossum J, Koopman PC, (1960). Receptor reserve and threshold phenomena. I. Theory and experiments with autonomic drugs tested on isolated organs. Arch Int Pharmacodyn Ther 127: 459-478.
3. Armstrong RA, Jones RL, (1988). Potentiation by AH6809 of iloprost-induced rises in platelet cyclic AMP levels. Br J Pharmacol 94 (Suppl.): 404P.
4. 1 derivatives in the cardiovascular system. Br J Pharmacol 84: 71-80.
5. 3 antagonists. Bioorg Med Chem Lett 15: 527-530.
6. Blaylock NA, Wilson VG, (1995). Pharmacological characterization of noradrenaline-induced contractions of the porcine isolated palmar lateral vein and palmar common digital artery. Br J Pharmacol 114: 694-702.
7. Breyer MD, Jacobson HR, Breyer RM, (1996). Functional and molecular aspects of renal prostaglandin receptors. J Am Soc Nephrol 7: 8-17.
8. Cao J, Shayibuzhati M, Tajima T, Kitazawa T, Taneike T, (2002). In vitro pharmacological characterization of the prostanoid receptor population in the non-pregnant porcine myometrium. Eur J Pharmacol 442: 115-123.
9. 2 (TP) receptor in the non-pregnant porcine myometrium and its role in regulation of spontaneous contractile activity. Eur J Pharmacol 485: 317-327.
10. Chen J, Senior J, Marshall K, Abbas F, Dinh H, Dinh T, et al. (2005). Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Br J Pharmacol 144: 493-501.
11. Christ GJ, Jean-Jacques M, (1991). Mutual-effect amplification of contractile responses elicited by simultaneous activation of alpha-1 adrenergic and 5-hydroxytryptamine2 receptors in isolated rat aorta. J Pharmacol Exp Ther 256: 553-561.
12. Coleman RA, Kennedy I, (1985). Characterisation of the prostanoid receptors mediating contraction of guinea-pig isolated trachea. Prostaglandins 29: 363-375.
13. 1 receptor blocking drug. Br J Pharmacol 85 (Suppl.): 273P.
14. 2-senstive (EP-) receptors. Br J Pharmacol 91 (Suppl.): 407P.
15. Coleman RA, Smith WL, Narumiya S, (1994). VIII International union of pharmacology classification of prostanoid receptors: properties distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46: 205-229.
16. De La Lande IS, Cannell VA, Waterson JG, (1966). The interaction of serotonin and noradrenaline on the perfused artery. Br J Pharmacol 28: 255-272.
17. 2-adrenoceptors. Br J Pharmacol 103: 1484-1492.
18. Edvinsson L, Ekblad E, HÃ¥kanson R, Wahlestedt C, (1984). Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol 83: 519-523.
19. 1 subtype. J Biol Chem 268: 26767-26772.
20. 3 prostanoid receptor. Bioorg Med Chem Lett 12: 2583-2586.
21. Griffin BW, Williams GW, Crider JY, Sharif NA, (1997). FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 cells: a pharmacological study. J Pharmacol Exp Ther 281: 845-854.
22. 2 antagonist and analgesic. Bioorg Med Chem Lett 4: 509-514.
23. Heptinstall S, Espinosa DI, Manolopoulos P, Glenn JR, White AE, Johnson A, et al. (2008). DG-041 inhibits the EP3 prostanoid receptor-a new target for inhibition of platelet function in atherosclerotic disease. Platelets 19: 605-613.
24. 2-induced constriction of porcine large cerebral arteries. J Cereb Blood Flow Metab 24: 1305-1316.
25. Jones RL, Peesapati V, Wilson NH, (1982). Antagonism of the thromboxane-sensitive contractile systems of the rabbit aorta, dog saphenous vein and guinea-pig trachea. Br J Pharmacol 76: 423-438.
26. 3-receptor in guinea-pig aorta: partial agonist action of the non-prostanoid ONO-AP-324. Br J Pharmacol 125: 1288-1296.
27. Jones RL, Shum WW, Gurney AM, (2002). Synergism between prostanoids and other vasoactive agents. J Card Surg 17: 436-438.
28. Jones RL, Giembycz MA, Woodward DF, (2009). Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 158: 104-145.
29. Jones RL, Woodward DF, Wang JW, Clark RL, (2010). Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations. Br J Pharmacol (in press).
30. Keery RJ, Lumley P, (1988). AH6809, a prostaglandin DP-receptor blocking drug on human platelets. Br J Pharmacol 94: 745-754.
31. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S, (1997). Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 122: 217-224.
32. Lawrence RA, Jones RL, Wilson NH, (1992). Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum. Br J Pharmacol 105: 271-278.
33. Leff P, (1987). An analysis of amplifying and potentiating interactions between agonists. J Pharmacol Exp Ther 243: 1035-1042.
34. McGrath JC, Dunn WR, Templeton AG, (1990). Physiological modulation of alpha-adrenoceptor and 5HT receptor expression in blood vessels. Blood Vessels 27: 146-152.
35. 2 receptor density and responsiveness in rat aortas and platelets. Am J Physiol 267: H887-H893.
36. Mattthews JS, Jones RL, (1993). Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues. Br J Pharmacol 108: 363-369.
37. 3-subtype. Br J Pharmacol 107: 352-355.
38. 3- and DP-receptors. Br J Pharmacol 111: 733-738.
39. Morrison KJ, Vanhoutte PM, (1992). Characterization of muscarinic receptors that mediate contraction of guinea-pig isolated trachea to choline esters: effect of removing epithelium. Br J Pharmacol 106: 672-676.
40. Naganawa A, Matsui T, Saito T, Ima M, Tatsumi T, Yamamoto S, et al. (2006). Discovery of heteroaryl sulfonamides as new EP1 receptor selective antagonists. Bioorg Med Chem 14: 6628-6639. (Pubitemid 44233312)
41. O'Connell M, Zeller W, Burgeson J, Mishra RK, Ramirez J, Kiselyov AS, et al. (2009). Peri-substituted hexahydro-indolones as novel, potent and selective human EP3 receptor antagonists. Bioorg Med Chem Lett 19: 778-782.
42. Okada Y, Hara A, Ma H, Xiao CY, Takahata O, Kohgo Y, et al. (2000). Characterization of prostanoid receptors mediating contraction of the gastric fundus and ileum: studies using mice deficient in prostanoid receptors. Br J Pharmacol 131: 745-755.
43. Schlemper V, Medeiros R, Ferreira J, Campos MM, Calixto JB, (2005). Mechanisms underlying the relaxation response induced by bradykinin in the epithelium-intact guinea-pig trachea in vitro. Br J Pharmacol 145: 740-750.
44. 2/prostaglandin endoperoxide receptor in rabbit aorta. Regulation by dexamethasone. Circ Res 67: 1562-1569.
45. 3 and FP prostaglandin receptor binding sites in bovine corpus luteum: characterization and correlation with functional data. J Pharmacol Exp Ther 286: 1094-1102.
46. Sharif NA, Kelly CR, Crider JY, (2002). Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther 18: 313-324.
47. Stupecky GL, Murray DL, Purdy RE, (1986). Vasoconstrictor threshold synergism and potentiation in the rabbit isolated thoracic aorta. J Pharmacol Exp Ther 238: 802-828.
48. Sugimoto Y, Narumiya S, (2007). Prostaglandin E receptors. J Biol Chem 282: 11613-11617.
49. Wahlestedt C, Edvinsson L, Ekblad E, HÃ¥kanson R, (1985). Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther 234: 735-741.
50. Wallis SJ, Martin W, (2000). Conditions permitting suppression of stretch-induced and vasoconstrictor tone by basal nitric oxide in porcine cerebral artery. Br J Pharmacol 130: 567-574.
51. 2-Adrenoceptor agonists enhance responses to certain other vasoconstrictor agonists in rat tail artery. Br J Pharmacol 96: 539-546.
52. Yildiz O, Smith JR, Purdy RE, (1998). Serotonin and vasoconstrictor synergism. Life Sci 62: 1723-1732.
53. 2/prostaglandin endoperoxide receptors in aorta. Eur J Pharmacol 317: 91-96.